Driving performance in adults with ADHD: Results from a randomized, waiting list controlled trial with atomoxetine

Sobanski, Esther; Sabljic, D.; Alm, Barbara; Dittmann, Ralf W.; Wehmeier, Peter M.; Skopp, Gisela; Strohbeck-Kühner, Peter

doi:10.1016/j.eurpsy.2012.08.001

Cited by 37 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies address medical treatment of ADHD-drivers and effects on driving behavior.. Driving contexts vary between real traffic (Lambert 1995;Cox et al 2000 and and experiments in driving simulators (Cox et al 2000(Cox et al , 2004(Cox et al , 2006Barkley et al 2005 and2007;Kay et al 2009;Sobanski et al 2012;Biederman et al 2012).…”

Section: Adhd and Road Safetymentioning

confidence: 99%

ADHD and relative risk of accidents in road traffic: A meta-analysis

Vaa

2014

Accident Analysis & Prevention

153

126

View full text Add to dashboard Cite

The present meta-analysis is based on 16 studies comprising 32 results. These studies provide sufficient data to estimate relative accident risks of drivers with ADHD. The overall estimate of relative risk for drivers with ADHD is 1.36 (95% CI: 1.18; 1.57) without control for exposure, 1.29 (1.12; 1.49) when correcting for publication bias, and 1.23 (1.04; 1.46) when controlling for exposure. A relative risk (RR) of 1.23 is exactly the same as found for drivers with cardiovascular diseases. The long-lasting assertion that "ADHD-drivers have an almost fourfold risk of accident compared to non-ADHD-drivers", which originated from Barkley et al.'s study of 1993, is rebutted. That estimate was associated with comorbid Oppositional Defiant Disorder (ODD) and/or Conduct Disorder (CD), not with ADHD, but the assertion has incorrectly been maintained for two decades. The present study provides some support for the hypothesis that the relative accident risk of ADHD-drivers with comorbid ODD, CD and/or other conduct problems, is higher than that of ADHD-drivers without these comorbidities. The estimated RRs were 1.86 (1.27; 2.75) in a sample of ADHD-drivers in which a majority had comorbid ODD and/or CD compared to 1.31 (0.96; 1.81) in a sample of ADHD-drivers with no comorbidity. Given that ADHD-drivers most often seem to drive more than controls, and the fact that a majority of the present studies lack information about exposure, it seems more probable that the true RR is lower rather than higher than 1.23. Also the assertion that ADHD-drivers violate traffic laws more often than other drivers should be modified: ADHD-drivers do have more speeding violations, but no more drunk or reckless driving citations than drivers without ADHD. All accident studies included in the meta-analysis fail to acknowledge the distinction between deliberate violations and driving errors. The former are known to be associated with accidents, the latter are not. A hypothesis that ADHD-drivers speed more frequently than controls because it stimulates attention and reaction time is suggested.

show abstract

Section: Adhd and Road Safetymentioning

confidence: 99%

ADHD and relative risk of accidents in road traffic: A meta-analysis

Vaa

2014

Accident Analysis & Prevention

153

126

View full text Add to dashboard Cite

show abstract

“…Een aantal studies onderzocht rijgedrag tijdens een rit op de weg [27,[67][68][69][70][71][72][73][74]. Deze bevestigen de bevindingen uit de tests met de rijsimulator.…”

Section: Wat Zijn De Effecten Van Farmaceutische Behandeling Op Het Runclassified

“…Daarnaast is aangetoond dat ook niet-stimulantia (atomoxetine), die eveneens worden gebruikt voor de behandeling van ADHD, de rijvaardigheid van personen met ADHD kunnen verbeteren. Deze effecten lijken echter niet erg stabiel te zijn [56,72,79].…”

Section: Conclusieunclassified

Autorijden met ADHD

et al. 2016

View full text Add to dashboard Cite

“…For ATX, these now currently exist as high responder rates using valid and robust definitions of response, the only positive trial in adult ADHD to show maintenance of response over a total of 1 year, and real-world evidence of improvements in crime reduction 4 and driving. 5 The overall view of the Medicines and Healthcare products Regulatory Agency assessor is thus of additional importance. 'In conclusion ATX has been shown to have significant efficacy in this patient population which is considered to outweigh the potential risks, provided patients are appropriately selected for treatment as specified in the SPC.…”

Section: Dear Sirmentioning

confidence: 99%